上半年亏损超4000万元 深圳这家医疗企业递表港交所

Core Viewpoint - Shenzhen Micotian Biomedical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its capital market journey, with the aim to enhance market expansion and R&D capabilities [1] Group 1: Company Overview - Micotian is a global provider of medical solutions, offering a comprehensive product portfolio that meets clinical needs across various healthcare settings, including hospitals and community health centers [2] - The company has commercialized over 50 life support products, 80 minimally invasive products, and 210 in vitro diagnostic products, with its products distributed in over 140 countries and regions [2] Group 2: Financial Performance - The company has faced continuous losses in recent years, with reported revenues of approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million for the six months ending June 30 in 2022, 2023, 2024, and 2025 respectively, alongside losses of RMB 226.16 million, RMB 64.51 million, RMB 96.62 million, and RMB 40.97 million [3][5] - Despite being a market leader in certain medical segments, the company reported a loss exceeding RMB 40 million in the first half of the year [3] Group 3: Product Segments - In the life support sector, Micotian has developed innovative products, including the world's first remote infusion control system and various infusion pumps, maintaining the top sales position in China from 2018 to 2024 [4] - The minimally invasive product sales have shown consistent growth, increasing from RMB 38.6 million in 2022 to RMB 58.65 million in 2023, and further to RMB 72.13 million in 2024 [6] - The in vitro diagnostic segment also experienced growth, with revenues rising from RMB 11.55 million in 2022 to RMB 16.26 million in 2023, and then to RMB 18.4 million in 2024 [7]